ImmunityBio Statistics

Total Valuation

ImmunityBio has a market cap or net worth of $9.12 billion. The enterprise value is $9.87 billion.

Market Cap	9.12B
Enterprise Value	9.87B

Important Dates

The next estimated earnings date is Tuesday, August 4, 2026, before market open.

Earnings Date	Aug 4, 2026
Ex-Dividend Date	n/a

Share Statistics

ImmunityBio has 1.05 billion shares outstanding. The number of shares has increased by 29.76% in one year.

Current Share Class	1.05B
Shares Outstanding	1.05B
Shares Change (YoY)	+29.76%
Shares Change (QoQ)	+3.76%
Owned by Insiders (%)	28.24%
Owned by Institutions (%)	17.76%
Float	394.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	64.71
Forward PS	38.19
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	69.98
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.67

Current Ratio	6.67
Quick Ratio	6.24
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.33

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-34.38%
Return on Invested Capital (ROIC)	-67.01%
Return on Capital Employed (ROCE)	-45.17%
Weighted Average Cost of Capital (WACC)	5.14%
Revenue Per Employee	$204,019
Profits Per Employee	-$1.24M
Employee Count	691
Asset Turnover	0.30
Inventory Turnover	0.21

Taxes

In the past 12 months, ImmunityBio has paid $108,000 in taxes.

Income Tax	108,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +215.58% in the last 52 weeks. The beta is 0.10, so ImmunityBio's price volatility has been lower than the market average.

Beta (5Y)	0.10
52-Week Price Change	+215.58%
50-Day Moving Average	7.58
200-Day Moving Average	5.27
Relative Strength Index (RSI)	66.98
Average Volume (20 Days)	13,458,113

Short Selling Information

The latest short interest is 135.15 million, so 12.90% of the outstanding shares have been sold short.

Short Interest	135.15M
Short Previous Month	132.14M
Short % of Shares Out	12.90%
Short % of Float	34.30%
Short Ratio (days to cover)	9.31

Income Statement

In the last 12 months, ImmunityBio had revenue of $140.98 million and -$854.53 million in losses. Loss per share was -$0.89.

Revenue	140.98M
Gross Profit	140.04M
Operating Income	-261.39M
Pretax Income	-854.50M
Net Income	-854.53M
EBITDA	-245.41M
EBIT	-261.39M
Loss Per Share	-$0.89

Full Income Statement

Balance Sheet

The company has $380.88 million in cash and $1.12 billion in debt, giving a net cash position of -$743.73 million or -$0.71 per share.

Cash & Cash Equivalents	380.88M
Total Debt	1.12B
Net Cash	-743.73M
Net Cash Per Share	-$0.71
Equity (Book Value)	-869.13M
Book Value Per Share	-0.83
Working Capital	385.00M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$294.39 million and capital expenditures -$4.50 million, giving a free cash flow of -$298.89 million.

Operating Cash Flow	-294.39M
Capital Expenditures	-4.50M
Depreciation & Amortization	15.98M
Net Borrowing	75.90M
Free Cash Flow	-298.89M
FCF Per Share	-$0.29

Full Cash Flow Statement

Margins

Gross Margin	99.34%
Operating Margin	-185.41%
Pretax Margin	-606.12%
Profit Margin	n/a
EBITDA Margin	-174.08%
EBIT Margin	-185.41%
FCF Margin	n/a

Dividends & Yields

ImmunityBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.76%
Shareholder Yield	-29.76%
Earnings Yield	-9.37%
FCF Yield	-3.28%

Analyst Forecast

The average price target for ImmunityBio is $13.00, which is 49.25% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$13.00
Price Target Difference	49.25%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (3Y)	131.55%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ImmunityBio has an Altman Z-Score of -8.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.48
Piotroski F-Score	3